What is CJC-1295?
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog built from the active hGRF(1-29) sequence. Its amino-acid substitutions and albumin-binding extension are designed to resist breakdown and keep the pituitary GHRH signal active longer than native GHRH fragments.[3][16]
The defining feature is its albumin-binding tail. After injection, that group can attach to circulating albumin, which acts like a carrier protein in blood; this is why CJC-1295 is discussed as the long-acting form while Modified GRF 1-29 is treated as shorter acting.[3][16]
Biologically, CJC-1295 does not replace growth hormone directly. It stimulates the pituitary GHRH receptor pathway, and human studies show downstream GH and IGF-1 biomarker increases when the pituitary GH axis can respond.[1][2]
The naming can be messy. CJC-1295, CJC-1295 without DAC, Modified GRF 1-29, and blends with GH secretagogues are not interchangeable; this page uses CJC-1295 to mean the long-acting albumin-binding form unless a section says otherwise.[16][3] For more context, read the CJC-1295 DAC and no-DAC comparison.
What CJC-1295 is investigated for
CJC-1295 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
GH-axis stimulation and IGF-1 biomarker response
Injectable
GH-axis stimulation and IGF-1 biomarker response
Injectable
This is the best-supported CJC-1295 claim: human evidence shows sustained GH and IGF-1 biomarker response after subcutaneous dosing.[1][2]
Human evidence
In healthy adults, subcutaneous CJC-1295 produced dose-dependent mean plasma GH increases of 2- to 10-fold for six days or more and mean plasma IGF-1 increases of 1.5- to 3-fold for 9-11 days after single dosing. A separate study found increased trough and mean GH with preserved pulsatility.[1][2]
Lean-mass and fat-loss support
Injectable
Lean-mass and fat-loss support
Injectable
Lean-mass and fat-loss support are biologically plausible for CJC-1295 because the peptide sustains GH and IGF-1 signaling, but direct human outcome evidence remains weak.[1][5]
Human evidence
Interest centers on lean-mass support, fat-mass changes, and weight-trend changes downstream of GH and IGF-1 signaling. Human CJC-1295 studies show sustained GH and IGF-1 biomarker increases, but they did not establish controlled DEXA, waist, visceral-fat, or fat-loss outcomes.[1][2]
Animal / mechanistic evidence
In a GHRH-knockout mouse deficiency model, daily CJC-1295 supported normal growth and tissue-mass-related measures. That strengthens the GH-axis rationale, but it is not the same as healthy-adult lean-mass or fat-loss evidence.[5]
Exercise recovery and training adaptation
Injectable
Exercise recovery and training adaptation
Injectable
Recovery is commonly discussed with CJC-1295, but it should be shown as an indirect GH-axis claim until outcome-specific human evidence is available.[1][4]
Sleep quality
Injectable
Sleep quality
Injectable
Sleep quality is a common tracking claim for CJC-1295, but the current evidence supports GH-axis physiology, not a proven sleep benefit.[2]
Human evidence
CJC-1295 has not shown controlled sleep-quality outcomes in the reviewed human evidence. The sleep rationale comes from overnight GH physiology and preserved GH pulsatility, not from validated sleep endpoints.[2]
Anti-aging and vitality support
Injectable
Anti-aging and vitality support
Injectable
Anti-aging and vitality belong on the page because readers search for them, but they should remain low-confidence outcome claims rather than proven benefits.[1][4]
Evidence snapshot
Overall confidence
CJC-1295 has stronger human biomarker evidence than many research peptides, but weaker clinical-outcome evidence than approved GH-axis drugs. The best-supported statement is that it can sustain GH and IGF-1 biomarker increases after subcutaneous administration.[1][2][17]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human pharmacodynamic support is strongest for GH and IGF-1 biomarkers: GH rose for six days or more, IGF-1 rose for 9-11 days after single dosing, and repeated dosing kept mean IGF-1 above baseline for up to 28 days.[1]
Animal / preclinical
Animal studies support the albumin-binding GHRH mechanism. Rat work identified CJC-1295 as a long-lasting hGRF(1-29) analog, and GHRH-knockout mice treated once daily maintained normal growth and body composition. This supports GH-axis pharmacology, not human outcome claims.[3][5]
Mechanism support
Mechanistic support is coherent: CJC-1295 is a modified GHRH analog, the DAC form binds albumin, and human studies show GH-axis activation. FDA notes that DAC and non-DAC forms should not be treated as interchangeable.[3][2][16]
Forms & administration
CJC-1295 is primarily discussed as a subcutaneous, long-acting GHRH analog. Route, albumin-binding form, concentration, product quality, and monitoring matter because sustained GH/IGF-1 signaling depends on systemic exposure.[1][16][15]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
What to expect
First week
Early sustained GH and IGF-1 biomarker elevation after subcutaneous dosing, with practical notes around sleep, recovery, water retention, and appetite.[1][2]
Days 9-11
Persistent mean plasma IGF-1 increases after a single CJC-1295 dose, which is why albumin-binding CJC-1295 is scheduled differently from short-acting GHRH analogs.[1]
Weeks 4-12
Sustained GH/IGF-1 lab movement, weight trend, body-composition notes, sleep, training tolerance, and recovery patterns against baseline.[1][15]
After stopping
Gradual return-toward-baseline pattern for GH/IGF-1 biomarkers, weight, sleep notes, and training markers after long-acting exposure ends.[1][15]
Safety profile
CJC-1295 safety should be treated as endocrine-active, route-specific, and unresolved for long-term non-study use. Early human studies reported no serious adverse reactions, but FDA later identified serious adverse events associated with CJC-1295, limited clinical data, and peptide compounding concerns around immunogenicity, impurities, and API characterization.[1][15][16]
Common side effects
Cautions
What we don't know
Decision-changing unknowns include long-term safety, repeated non-study use, product interchangeability, DAC versus no-DAC risk differences, cancer- or growth-factor-sensitive conditions, special-population safety, and whether outcome benefits justify endocrine exposure.[15][16]
Who CJC-1295 is not for
Route-specific avoid and medical-review notes:
-
Competitive athletes
Competitive athletes should avoid CJC-1295 unless their anti-doping authority provides route-specific written clearance. WADA lists CJC-1295 as prohibited under growth hormone releasing factors.
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Other GH-axis drugs or secretagogues
This is a theoretical additive-exposure caution. Combining CJC-1295 with other GH-axis agents, growth hormone, GHRPs, or secretagogues may make GH/IGF-1 exposure and side-effect interpretation harder to manage.[1][2][15]
- Glucose-active medications
This is a theoretical endocrine-monitoring caution. Because GH/IGF-1 signaling intersects with metabolic regulation, people using insulin, diabetes drugs, or weight-management medications need clinician review rather than app-only scheduling.[1]
Pairing notes
Commonly included in these stacks
Not recommended with
This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[1][16][18]
CJC variants provide different exposure profiles but stimulate the same GHRH receptor pathway. Combining them duplicates GH/IGF-1 stimulation and makes exposure and monitoring harder to interpret.[1][19][16]
Tesamorelin and CJC-1295 both stimulate GHRH receptors to increase growth-hormone and IGF-1 signaling. Using both duplicates the same upstream GH-axis mechanism without an established combined regimen.[20][1][16]
Sermorelin and CJC-1295 both stimulate the GHRH receptor. CJC-1295 extends exposure, but overlapping the two still duplicates upstream GH/IGF-1 stimulation.[21][1][16]
Related peptides
Regulatory status
United States
United States: not FDA-approved for human use as a drug. FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug, and FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with safety concerns.[17][16][15]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved The openFDA Drugs@FDA query for CJC-1295 returned no matching approved drug product, and FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug.[17][16] | Flagged FDA's safety-risk page lists CJC-1295 under bulk substances nominated but withdrawn and flags immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data.[15][16] |
Injectable
FDA drug approval
Not ApprovedThe openFDA Drugs@FDA query for CJC-1295 returned no matching approved drug product, and FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug.[17][16]
503A compounding
FlaggedFDA's safety-risk page lists CJC-1295 under bulk substances nominated but withdrawn and flags immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data.[15][16]
International
International status is route-, product-, and claim-specific. No country-specific therapeutic approval outside the United States is established in this review.
Sports & competition
Sports competition: prohibited under WADA S2 growth hormone releasing factors. The prohibition applies regardless of whether the product is labeled as research use, compounded, or clinic supplied.
How it works
The starting point is the natural GHRH signal. GHRH normally tells pituitary somatotroph cells to release growth hormone. CJC-1295 is designed to imitate and extend that signal rather than replace GH itself.[2][16]
The albumin-binding feature changes the pharmacology. Jette and colleagues used a maleimido albumin-binding strategy, and FDA review materials describe the MPA group binding covalently to albumin's cysteine-34 residue. In plain terms, albumin works like a circulation carrier that can make the signal last much longer.[3][16]
In human studies, that design translated into sustained endocrine biomarkers: GH rose for days, IGF-1 rose for longer, and pulsatile GH secretion was preserved while baseline trough GH increased. Those details matter because a flat GH replacement exposure and a stimulated pituitary signal are not the same thing.[1][2]
The limitation is translation. GH and IGF-1 sit upstream of body composition, recovery, and sleep biology, but raising upstream biomarkers does not automatically prove a downstream outcome. Stronger claims require outcome trials, long-term safety data, and route-specific product-quality evidence.[4][15]
Research gaps & open questions
What the current literature has not yet settled about CJC-1295:
Controlled trials still need to show whether CJC-1295 improves fat loss, lean mass, sleep, recovery, or symptoms—not only growth hormone and IGF-1 blood levels.[1]
Long-term safety remains unclear, especially with repeated use or persistently high IGF-1 in people with endocrine disease, blood-sugar problems, cancer risk, or other special health considerations.[1][15]
Independent testing needs to show the identity, purity, stability, and immune-reaction risk of compounded CJC-1295 products.[15][16]
The DAC and no-DAC forms need separate dosing, safety, and evidence guidance; they should not be treated as interchangeable.[16][3]
Common questions
What is CJC-1295 investigated for?
CJC-1295 is commonly investigated or discussed across GH-axis stimulation, body-composition outcomes, exercise recovery, sleep quality, and anti-aging or vitality support. The strongest direct support is GH and IGF-1 biomarker response; the other outcome areas need their own human evidence.[1][2][5][4]
Is CJC-1295 the same as CJC-1295 without DAC?
What is the CJC-1295 dose?
Is CJC-1295 safe?
Myths & misconceptions
Myth
If CJC-1295 raises GH and IGF-1, it is proven for muscle, sleep, recovery, and anti-aging.
Myth
Long-acting CJC-1295 and CJC-1295 no DAC are basically the same.
Reality
They should be treated as different pharmacology problems. FDA review materials distinguish DAC and non-DAC CJC-1295-related substances and caution that albumin-binding pharmacology cannot be extrapolated to the non-DAC form.[16]
Myth
Research-use or compounded CJC-1295 is safe if the schedule looks common.
History & discovery
CJC-1295 moved from albumin-binding GHRH analog design into early human GH-axis trials, then into discontinued drug-development and later compounding/research-market visibility. Its public reputation now runs ahead of completed clinical outcome evidence.[3][1][15]
Jette and colleagues identified CJC-1295 as a long-lasting hGRF(1-29) analog after testing maleimido hGRF-albumin bioconjugates in vitro and in rats.[3]
Randomized, placebo-controlled ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases after subcutaneous CJC-1295, and a separate study reported preserved GH pulsatility.[1][2]
A serum proteomics study examined biomarker changes after CJC-1295 exposure, while analytical work identified CJC-1295 in an unknown pharmaceutical preparation and framed it as a WADA-prohibited GH-releasing factor.[4][13]
FDA PCAC materials evaluated five CJC-1295-related bulk substances for 503A compounding and FDA's safety-risk page lists CJC-1295 under nominated-but-withdrawn substances. WADA's 2026 prohibited-list materials identify CJC-1295 as a prohibited growth hormone releasing factor.[16][15]
21 citations
Show citationsHide citations
- [1]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.
- [2]Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.
- [3]Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.PubMed / Endocrinology, 2005. animal.
- [4]Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.PubMed Central / Growth Hormone & IGF Research, 2009. human clinical.
- [5]Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.PubMed / American Journal of Physiology-Endocrinology and Metabolism, 2006. animal.
- [6]Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.PubMed / JBJS Reviews, 2026. review.
- [7]Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.PubMed / Sports Medicine, 2026. review.
- [8]Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.PubMed / American Journal of Sports Medicine, 2026. review.
- [9]Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.PubMed / Substance Use & Misuse, 2016. review.
- [10]Advances in the detection of growth hormone releasing hormone synthetic analogs.PubMed / Drug Testing and Analysis, 2021. ex vivo.
- [11]An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.PubMed / Drug Testing and Analysis, 2019. ex vivo.
- [12]A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.PubMed / Drug Testing and Analysis, 2019. ex vivo.
- [13]Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.PubMed / Drug Testing and Analysis, 2010. regulatory.
- [14]Glycine-modified growth hormone secretagogues identified in seized doping material.PubMed / Drug Testing and Analysis, 2019. regulatory.
- [15]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration. regulatory.
- [16]FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee MeetingU.S. Food and Drug Administration, 2024. regulatory.
- [17]openFDA Drugs@FDA query for CJC-1295openFDA / U.S. Food and Drug Administration. database query.
- [18]NORDITROPIN somatropin injection prescribing informationU.S. Food and Drug Administration. official guidance.
- [19]Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.PubMed / Journal of Clinical Endocrinology and Metabolism, 1994. human clinical.
- [20]EGRIFTA WR- tesamorelin kitDailyMed / National Library of Medicine. official guidance.
- [21]Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism, 1996 Mar. human clinical.


